Easywell Biomedicals, Inc. (TPEX:1799)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
29.55
-1.75 (-5.59%)
Mar 3, 2026, 1:19 PM CST
-55.36%
Market Cap 3.90B
Revenue (ttm) 588.89M
Net Income (ttm) -64.44M
Shares Out 124.69M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 406,222
Average Volume 117,773
Open 31.30
Previous Close 31.30
Day's Range 28.70 - 31.40
52-Week Range 28.80 - 83.70
Beta 0.11
RSI 36.33
Earnings Date Mar 27, 2026

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angi... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 1799
Full Company Profile

Financial Performance

In 2024, Easywell Biomedicals's revenue was 540.44 million, an increase of 98.96% compared to the previous year's 271.63 million. Losses were -97.47 million, -32.70% less than in 2023.

Financial Statements

News

There is no news available yet.